2024
USPSTF Colorectal Cancer Screening Recommendation and Uptake for Individuals Aged 45 to 49 Years
Siddique S, Wang R, Yasin F, Gaddy J, Zhang L, Gross C, Ma X. USPSTF Colorectal Cancer Screening Recommendation and Uptake for Individuals Aged 45 to 49 Years. JAMA Network Open 2024, 7: e2436358. PMID: 39361285, PMCID: PMC11450516, DOI: 10.1001/jamanetworkopen.2024.36358.Peer-Reviewed Original ResearchConceptsUS Preventive Services Task ForceUS Preventive Services Task Force recommendationsColorectal cancer screening uptakeAverage-risk individualsScreening uptakeHigher socioeconomic statusSocioeconomic statusScreening recommendationsColorectal cancerColorectal cancer screening recommendationsPreventive Services Task ForceCohort studyCancer screening recommendationsScreening uptake ratesInterrupted time series analysisLow socioeconomic statusPrivate insurance beneficiariesScreening ratesSocioeconomic disparitiesRetrospective cohort studyMain OutcomesPotential disparitiesEvaluate changesClaims dataAbsolute changeAssociations Between Prostate Magnetic Resonance Imaging, Genomic Testing, and Treatment for Localized Prostate Cancer.
Sundaresan V, Wang R, Long J, Sprenkle P, Seibert T, Loeb S, Cooperberg M, Catalona W, Ma X, Gross C, Leapman M. Associations Between Prostate Magnetic Resonance Imaging, Genomic Testing, and Treatment for Localized Prostate Cancer. Urology Practice 2024, 101097upj0000000000000679. PMID: 39196719, DOI: 10.1097/upj.0000000000000679.Peer-Reviewed Original ResearchLocalized prostate cancerClinically localized prostate cancerHigh-risk diseaseProstate MRIProstate cancerTreatment intensificationIntensified treatmentGenomic testingTreated patientsProstate magnetic resonance imagingEnd Results databaseLong-term patient outcomesProstate cancer prognosisRetrospective cohort studyAssociated with decreased oddsRisk stratification toolPrimary study outcomeAssociated with increased oddsMagnetic resonance imagingResults databaseStratification toolTreatment patientsCohort studyRisk strataCancer prognosisSystemic Anticancer Therapy and Overall Survival in Patients With Very Advanced Solid Tumors
Canavan M, Wang X, Ascha M, Miksad R, Showalter T, Calip G, Gross C, Adelson K. Systemic Anticancer Therapy and Overall Survival in Patients With Very Advanced Solid Tumors. JAMA Oncology 2024, 10: 887-895. PMID: 38753341, PMCID: PMC11099840, DOI: 10.1001/jamaoncol.2024.1129.Peer-Reviewed Original ResearchNational Quality ForumQuintile 5Quintile 1Improve end-of-life careEnd-of-life careCohort studyNationwide population-based cohort studyPopulation-based cohort studyEnd of lifeElectronic health record databaseHealth care practicesColorectal cancerPopulation of patientsCox proportional hazards modelsAmerican Society of Clinical OncologyQuality ForumCare practicesOverall survivalPayment incentivesProportional hazards modelHighest quintileMultivariate Cox proportional hazards modelQuintileFlatiron HealthHazard ratioCharacterization of time toxicity in older patients with metastatic breast cancer
Atre S, Soulos P, Kuderer N, Gross C, Baum L, Dinan M, Lustberg M. Characterization of time toxicity in older patients with metastatic breast cancer. Breast Cancer Research And Treatment 2024, 207: 541-550. PMID: 38816556, DOI: 10.1007/s10549-024-07379-7.Peer-Reviewed Original ResearchMetastatic breast cancerBone-modifying agentsComorbid medical conditionsOlder patientsBreast cancerRetrospective cohort studySEER-Medicare databaseTreatment typeCancer treatment modalityTreatment modalitiesSEER-MedicareCohort studyUnadjusted analysisPatientsAge-related impactCancer treatmentComorbiditiesDay patientsCancerRadiotherapyOlder ageMedical conditionsToxicityTreatmentSociodemographic factorsOpioid prescribing trends and pain scores among adult patients with cancer in a large health system.
Baum L, Soulos P, KC M, Jeffery M, Ruddy K, Lerro C, Lee H, Graham D, Liberatore M, Rivera D, Leapman M, Jairam V, Dinan M, Gross C, Park H. Opioid prescribing trends and pain scores among adult patients with cancer in a large health system. Journal Of Clinical Oncology 2024, 42: 11059-11059. DOI: 10.1200/jco.2024.42.16_suppl.11059.Peer-Reviewed Original ResearchDocumented painHealth systemOpioid prescribingOpioid prescriptionsOpioid prescribing trendsYale New Haven Health SystemPrescribing trendsMetastatic cancerDocumented pain scoresUS health systemOpioid usePain scoresAdult patientsCalculated predicted probabilitiesFlowsheet dataRetrospective cohort studyRelated harmSolid tumor malignanciesCohort studyCancer painPrescribingContext of cancer treatmentStudy criteriaPainSurgery cohortPD45-10 PROSTATE-SPECIFIC MEMBRANE ANTIGEN IMAGING FINDINGS AND SUBSEQUENT CLINICAL MANAGEMENT AMONG PATIENTS WITH BIOCHEMICAL RECURRENT PROSTATE CANCER: A RETROSPECTIVE COHORT STUDY
Leapman M, Rabil M, Ghaffar U, Long J, Westvold S, Sprenkle P, Kim I, Saperstein L, Fallah J, Suzman D, Lerro C, Xu J, Kluetz P, Kunst N, Wang S, Ma X, Gross C, Karnes R. PD45-10 PROSTATE-SPECIFIC MEMBRANE ANTIGEN IMAGING FINDINGS AND SUBSEQUENT CLINICAL MANAGEMENT AMONG PATIENTS WITH BIOCHEMICAL RECURRENT PROSTATE CANCER: A RETROSPECTIVE COHORT STUDY. Journal Of Urology 2024, 211: e971. DOI: 10.1097/01.ju.0001008792.09108.b4.10.Peer-Reviewed Original ResearchImmunotherapy utilization patterns in patients with advanced cancer and autoimmune disease
Li H, Huntington S, Gross C, Wang S. Immunotherapy utilization patterns in patients with advanced cancer and autoimmune disease. PLOS ONE 2024, 19: e0300789. PMID: 38625861, PMCID: PMC11020359, DOI: 10.1371/journal.pone.0300789.Peer-Reviewed Original ResearchConceptsAutoimmune diseasesImmunotherapy cycleFirst-lineNon-small cell lung cancerAdvanced cancerFirst-line immunotherapyOverall treatment toleranceCell lung cancerRenal cell carcinomaRetrospective cohort studyAssociated with lower oddsAdvanced melanomaCell carcinomaTreatment toleranceAbsolute contraindicationImmunotherapyConsensus guidelinesImprove cancer survivalLung cancerCohort studyClinical variablesCancer patientsAcademic centersPatientsIncidence rateArea Vulnerability and Disparities in Therapy for Patients With Metastatic Renal Cell Carcinoma
Rahman S, Long J, Westvold S, Leapman M, Spees L, Hurwitz M, McManus H, Gross C, Wheeler S, Dinan M. Area Vulnerability and Disparities in Therapy for Patients With Metastatic Renal Cell Carcinoma. JAMA Network Open 2024, 7: e248747. PMID: 38687479, PMCID: PMC11061765, DOI: 10.1001/jamanetworkopen.2024.8747.Peer-Reviewed Original ResearchConceptsMetastatic renal cell carcinomaArea-level measuresRenal cell carcinomaPatient-level factorsSystemic therapyEthnic disparitiesRelative risk ratiosSocially vulnerable areasCell carcinomaMeasures of social vulnerabilityMedicare beneficiariesCohort studyFee-for-service Medicare Parts AOdds ratioReceipt of systemic therapyLogistic regressionArea-level characteristicsAssociated with lack of treatmentNon-Hispanic blacksRetrospective cohort studyIndividual-level demographicsNon-Hispanic whitesAssociated with disparitiesUS Medicare beneficiariesMeasures of disadvantageTemporal and regional patterns of prostate cancer positron emission tomography imaging among commercial insurance beneficiaries in the United States.
Leapman M, Long J, Westvold S, Rabil M, Sprenkle P, Kim I, Saperstein L, Fallah J, Suzman D, Lerro C, Xu J, Kluetz P, Karnes R, Kunst N, Wang S, Ma X, Gross C. Temporal and regional patterns of prostate cancer positron emission tomography imaging among commercial insurance beneficiaries in the United States. Journal Of Clinical Oncology 2024, 42: 34-34. DOI: 10.1200/jco.2024.42.4_suppl.34.Peer-Reviewed Original ResearchProportion of patientsProstate cancerPSMA-PETPET imagingProstate specific membrane antigen positron emission tomographyDiagnosis of prostate cancerProstate cancer visualizationPSMA PET imagingPSMA-targeted agentsPositron emission tomography imagingCochran-Armitage testDynamic cohort studyPositron emission tomographyCommercial insurance beneficiariesEmission tomography imagingChi-square testCancer visualizationCholine tracersCohort studyProstateTreatment decisionsBlue Cross Blue Shield AxisCochran-ArmitageEmission tomographyInsurance beneficiariesIntegrating 4 methods to evaluate physical function in patients with cancer (In4M): protocol for a prospective cohort study
Thanarajasingam G, Kluetz P, Bhatnagar V, Brown A, Cathcart-Rake E, Diamond M, Faust L, Fiero M, Huntington S, Jeffery M, Jones L, Noble B, Paludo J, Powers B, Ross J, Ritchie J, Ruddy K, Schellhorn S, Tarver M, Dueck A, Gross C. Integrating 4 methods to evaluate physical function in patients with cancer (In4M): protocol for a prospective cohort study. BMJ Open 2024, 14: e074030. PMID: 38199641, PMCID: PMC10806877, DOI: 10.1136/bmjopen-2023-074030.Peer-Reviewed Original ResearchConceptsPhysical function assessmentPhysical functionFunctional assessmentEvaluation of physical functionElectronic health record dataEvaluate physical functionHealth record dataSpanish-speaking patientsDigital health technologiesBreast cancerProspective cohort studyClinician-reported outcomesCancer clinical trialsClinical decision-makingStudy questionnairePatient-centred evaluationHealth technologiesMeasure symptomsOncology practiceCohort studyRecord dataPatient's impressionMayo ClinicEnglish-speakingWearable sensors
2023
Total and treatment-related costs of care associated with in patients with metastatic renal cell carcinoma receiving targeted or immune therapy.
Rahman S, Long J, Westvold S, Wheeler S, Spees L, Leapman M, Hurwitz M, McManus H, Gross C, Dinan M. Total and treatment-related costs of care associated with in patients with metastatic renal cell carcinoma receiving targeted or immune therapy. JCO Oncology Practice 2023, 19: 28-28. DOI: 10.1200/op.2023.19.11_suppl.28.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaOral anticancer agentsInitial treatmentRetrospective cohort studyUse of immunotherapyYear of diagnosisRenal cell carcinomaDirect treatment costsMean Medicare paymentsMedicare paymentsMedicare Part DInitial therapyCohort studyMetastatic diagnosisCell carcinomaCombination therapyImmunotherapyMedicare beneficiariesPatientsAge 65Disease controlOlder ageStudy periodTherapyDiagnosisMutation-specific costs of advanced non-small cell lung cancer treatment.
Tan J, Yang S, Dinan M, Chiang A, Gross C, Wang S. Mutation-specific costs of advanced non-small cell lung cancer treatment. JCO Oncology Practice 2023, 19: 14-14. DOI: 10.1200/op.2023.19.11_suppl.14.Peer-Reviewed Original ResearchAdvanced non-small cell lung cancerNon-small cell lung cancerMean medication costsActionable gene alterationsMedication costsFirst-year costsReference groupAdvanced non-small cell lung cancer (NSCLC) treatmentNon-small cell lung cancer (NSCLC) treatmentCell lung cancer treatmentGene alterationsBiomarker resultsFlatiron Health databasePD-L1 resultsTherapy prolongs survivalRetrospective cohort studyCell lung cancerBiomarker test resultsLung cancer treatmentCost-effectiveness analysisCohort studyNovel immunotherapiesOverall cohortProlong survivalTreatment optionsTrends in new and persistent opioid use in older adults with and without cancer
Baum L, KC M, Soulos P, Jeffery M, Ruddy K, Lerro C, Lee H, Graham D, Rivera D, Leapman M, Jairam V, Dinan M, Gross C, Park H. Trends in new and persistent opioid use in older adults with and without cancer. Journal Of The National Cancer Institute 2023, 116: 316-323. PMID: 37802882, DOI: 10.1093/jnci/djad206.Peer-Reviewed Original ResearchAdditional opioid useNew opioid useOpioid useNon-metastatic cancerPersistent opioid useRetrospective cohort studySolid tumor malignanciesClinical strataEligible patientsNaïve patientsOpioid prescribingMetastatic patientsSurgery patientsCohort studySEER-MedicareMetastatic cancerPatientsTumor malignancyCancerOlder adultsSurgeryRandom sampleAdditional useChemotherapyPrescribingEstimating Breast Cancer Overdiagnosis After Screening Mammography Among Older Women in the United States.
Richman I, Long J, Soulos P, Wang S, Gross C. Estimating Breast Cancer Overdiagnosis After Screening Mammography Among Older Women in the United States. Annals Of Internal Medicine 2023, 176: 1172-1180. PMID: 37549389, PMCID: PMC10623662, DOI: 10.7326/m23-0133.Peer-Reviewed Original ResearchConceptsCumulative incidenceBreast cancerBreast cancer screeningUnscreened womenOlder womenCancer screeningBreast cancer-specific deathBreast cancer overdiagnosisService Medicare claimsRetrospective cohort studyCancer-specific deathBreast cancer deathsWomen 70 yearsHarms of overdiagnosisNational Cancer InstituteBreast cancer diagnosisCohort studyCancer overdiagnosisCancer deathSEER programMedicare claimsCancer InstituteOverdiagnosisGreater incidenceCancerCancer incidence among incarcerated and formerly incarcerated individuals: A statewide retrospective cohort study
Aminawung J, Soulos P, Oladeru O, Lin H, Gonsalves L, Puglisi L, Hassan S, Richman I, Wang E, Gross C. Cancer incidence among incarcerated and formerly incarcerated individuals: A statewide retrospective cohort study. Cancer Medicine 2023, 12: 15447-15454. PMID: 37248772, PMCID: PMC10417084, DOI: 10.1002/cam4.6162.Peer-Reviewed Original ResearchConceptsNon-Hispanic Black individualsScreen-detectable cancersStandardized incidence ratiosNon-Hispanic white individualsCancer incidenceGeneral populationStatewide retrospective cohort studyRetrospective cohort studyWhite individualsState tumor registryLower cancer incidenceBlack individualsHigher cancer incidenceIncarceration exposureCohort studyRetrospective cohortTumor RegistryIncidence ratiosIncarcerated individualsCancer screeningIncidence rateHigh incidenceConnecticut residentsEthnic strataIncidenceAssociation Between Age and Survival Trends in Advanced Non–Small Cell Lung Cancer After Adoption of Immunotherapy
Voruganti T, Soulos P, Mamtani R, Presley C, Gross C. Association Between Age and Survival Trends in Advanced Non–Small Cell Lung Cancer After Adoption of Immunotherapy. JAMA Oncology 2023, 9: 334-341. PMID: 36701150, PMCID: PMC9880865, DOI: 10.1001/jamaoncol.2022.6901.Peer-Reviewed Original ResearchConceptsAdvanced non-small cell lung cancerNon-small cell lung cancerImmune checkpoint inhibitorsUse of ICIsPatients 75 yearsCell lung cancerDrug Administration approvalCohort studyOlder patientsLung cancerAdministration approvalUS FoodAdoption of immunotherapyMedian overall survivalCancer-directed therapySubstantial survival benefitFirst US FoodCheckpoint inhibitorsStage IIIBClinical characteristicsICI useMedian survivalOverall survivalSurvival benefitSurvival gainEvolution of systemic therapy from 2015 to 2019 for older patients in the United States with metastatic renal cell carcinoma.
Chow R, Long J, Hassan S, Wheeler S, Spees L, Leapman M, Hurwitz M, McManus H, Gross C, Dinan M. Evolution of systemic therapy from 2015 to 2019 for older patients in the United States with metastatic renal cell carcinoma. Journal Of Clinical Oncology 2023, 41: 610-610. DOI: 10.1200/jco.2023.41.6_suppl.610.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaImmune checkpoint inhibitorsOral anti-cancer agentsNon-Hispanic white patientsSystemic therapyRenal cell carcinomaNHW patientsWhite patientsCell carcinomaMedicare beneficiariesService Medicare Parts ARetrospective cohort studyOverall treatment rateMedicare Part AIO therapyMRCC therapyAnti-cancer agentsCheckpoint inhibitorsCohort studyOlder patientsRandomized trialsSurvival improvementFirst therapyStudy criteriaTreatment receiptUse of Monitoring Tests Among Patients With Localized Prostate Cancer Managed With Observation
Leapman M, Wang R, Loeb S, Seibert T, Gaylis F, Lowentritt B, Brown G, Chen R, Lin D, Witte J, Cooperberg M, Catalona W, Gross C, Ma X. Use of Monitoring Tests Among Patients With Localized Prostate Cancer Managed With Observation. Journal Of Urology 2023, 209: 710-718. PMID: 36753746, DOI: 10.1097/ju.0000000000003159.Peer-Reviewed Original ResearchConceptsIntermediate-risk prostate cancerMixed-effects Poisson regressionPSA testingProstate biopsyProstate cancerEffects Poisson regressionMedicare beneficiariesPoisson regressionAdditional prostate biopsyRetrospective cohort studyProstate MRILocalized prostate cancerRepeat prostate biopsyRate of biopsyRace/ethnicityCensus tract povertyMedian followCohort studyMedian ageMonitoring testsProvider factorsPSA testClinical riskBiopsySociodemographic factors
2021
Differences by race in systemic oncologic end-of-life (EOL) care among patients with cancer.
Adelson K, Wang X, Ascha M, Miksad R, Showalter T, Calip G, Gross C, Canavan M. Differences by race in systemic oncologic end-of-life (EOL) care among patients with cancer. Journal Of Clinical Oncology 2021, 39: 137-137. DOI: 10.1200/jco.2020.39.28_suppl.137.Peer-Reviewed Original ResearchBlack patientsWhite patientsAggressive EOL careRetrospective cohort studyPractice-level factorsPractice-level characteristicsRacial differencesDe-identified databaseLogistic regression modelsAnti-cancer therapyElectronic health recordsImmunotherapy eraCohort studyICI useOncologic treatmentPayer cohortHigh patientEOL careAdjusted ratesOutcome measuresEOL treatmentMedicaid coveragePatientsPhysician ratioRoutine practice
2017
Physician volume and discontinuation of rituximab during lymphoma treatment.
Huntington S, Long J, Hoag J, Wang R, Zeidan A, Giri S, Gore S, Ma X, Gross C, Davidoff A. Physician volume and discontinuation of rituximab during lymphoma treatment. Journal Of Clinical Oncology 2017, 35: 6593-6593. DOI: 10.1200/jco.2017.35.15_suppl.6593.Peer-Reviewed Original ResearchNon-Hodgkin lymphomaEarly discontinuationRituximab discontinuationPhysician volumeProvider volumeEnd Results-Medicare dataB-cell non-Hodgkin lymphomaCell non-Hodgkin lymphomaCox proportional hazards modelDiscontinuation of rituximabSevere infusion reactionsRetrospective cohort studyImpact of discontinuationDays of initiationProportional hazards modelDose-dependent mannerRituximab cyclesRituximab initiationInfusion reactionsOverall survivalCohort studyPrimary outcomeSystemic treatmentLymphoma treatmentRelative risk